Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor)

pCPA File Number: 22896
Negotiation Status:
Concluded with an LOI
Indication(s):
Cystic fibrosis, F508del or responsive CFTR mutation, 2 years and older
Sponsor/Manufacturer:
Vertex Pharmaceuticals (Canada) Incorporated
CDA-AMC Project Number:
SR0837-000
pCPA Engagement Letter Issued:
Negotiation Process Concluded: